Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

88 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Patterns of drug resistance among newly diagnosed HIV-1 infected patients in Greece during the last decade: the crucial role of transmission networks.
Paraskevis D, Zavitsanou A, Magiorkinis E, Gargalianos P, Xylomenos G, Lazanas M, Chini M, Skoutelis A, Papastamopoulos V, Antoniadou A, Papadopoulos A, Psichogiou M, Daikos G, Vassilakis A, Chrysos G, Paparizos V, Kourkounti S, Sambatakou H, Kordossis T, Koratzanis G, Panagopoulos P, Maltezos E, Drimis S, Hatzakis A. Paraskevis D, et al. Among authors: kordossis t. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19742. doi: 10.7448/IAS.17.4.19742. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25397487 Free PMC article.
Increasing prevalence of HIV-1 subtype A in Greece: estimating epidemic history and origin.
Paraskevis D, Magiorkinis E, Magiorkinis G, Sypsa V, Paparizos V, Lazanas M, Gargalianos P, Antoniadou A, Panos G, Chrysos G, Sambatakou H, Karafoulidou A, Skoutelis A, Kordossis T, Koratzanis G, Theodoridou M, Daikos GL, Nikolopoulos G, Pybus OG, Hatzakis A; Multicentre Study on HIV Heterogeneity. Paraskevis D, et al. Among authors: kordossis t. J Infect Dis. 2007 Oct 15;196(8):1167-76. doi: 10.1086/521677. Epub 2007 Sep 13. J Infect Dis. 2007. PMID: 17955435
Effect of HIV type 1 subtype on virological and immunological response to combination antiretroviral therapy: evidence for a more rapid viral suppression for subtype A than subtype B-infected Greek individuals.
Paraskevis D, Touloumi G, Bakoyannis G, Paparizos V, Lazanas M, Gargalianos P, Chryssos G, Antoniadou A, Psichogiou M, Panos G, Katsarou O, Sambatakou H, Kordossis T, Hatzakis A; AMACS. Paraskevis D, et al. Among authors: kordossis t. AIDS Res Hum Retroviruses. 2013 Mar;29(3):461-9. doi: 10.1089/AID.2012.0143. Epub 2012 Nov 6. AIDS Res Hum Retroviruses. 2013. PMID: 23034083
Evaluation of the clinical sensitivity for the quantification of human immunodeficiency virus type 1 RNA in plasma: Comparison of the new COBAS TaqMan HIV-1 with three current HIV-RNA assays--LCx HIV RNA quantitative, VERSANT HIV-1 RNA 3.0 (bDNA) and COBAS AMPLICOR HIV-1 Monitor v1.5.
Katsoulidou A, Petrodaskalaki M, Sypsa V, Papachristou E, Anastassopoulou CG, Gargalianos P, Karafoulidou A, Lazanas M, Kordossis T, Andoniadou A, Hatzakis A. Katsoulidou A, et al. Among authors: kordossis t. J Virol Methods. 2006 Feb;131(2):168-74. doi: 10.1016/j.jviromet.2005.07.014. Epub 2005 Sep 27. J Virol Methods. 2006. PMID: 16194575
The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study.
Cain LE, Phillips A, Lodi S, Sabin C, Bansi L, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, de Wolf F, Bucher HC, Elzi L, Touloumi G, Vourli G, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Abgrall S, Costagliola D, Hernán MA; HIV-CAUSAL Collaboration. Cain LE, et al. AIDS. 2012 Aug 24;26(13):1691-705. doi: 10.1097/QAD.0b013e328354f497. AIDS. 2012. PMID: 22546987 Free PMC article.
Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries.
del Amo J, Moreno S, Bucher HC, Furrer H, Logan R, Sterne J, Pérez-Hoyos S, Jarrín I, Phillips A, Lodi S, van Sighem A, de Wolf W, Sabin C, Bansi L, Justice A, Goulet J, Miró JM, Ferrer E, Meyer L, Seng R, Toulomi G, Gargalianos P, Costagliola D, Abgrall S, Hernán MA; HIV-CAUSAL Collaboration. del Amo J, et al. Clin Infect Dis. 2012 May;54(9):1364-72. doi: 10.1093/cid/cis203. Epub 2012 Mar 28. Clin Infect Dis. 2012. PMID: 22460971 Free PMC article.
Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.
HIV-CAUSAL Collaboration; Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall S, Costagliola D, Hernán MA. HIV-CAUSAL Collaboration, et al. Clin Infect Dis. 2015 Apr 15;60(8):1262-8. doi: 10.1093/cid/ciu1167. Epub 2015 Jan 6. Clin Infect Dis. 2015. PMID: 25567330 Free PMC article.
Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen.
De Luca A, Flandre P, Dunn D, Zazzi M, Wensing A, Santoro MM, Günthard HF, Wittkop L, Kordossis T, Garcia F, Castagna A, Cozzi-Lepri A, Churchill D, De Wit S, Brockmeyer NH, Imaz A, Mussini C, Obel N, Perno CF, Roca B, Reiss P, Schülter E, Torti C, van Sighem A, Zangerle R, Descamps D; CHAIN and COHERE in EuroCoord. De Luca A, et al. Among authors: kordossis t. J Antimicrob Chemother. 2016 May;71(5):1352-60. doi: 10.1093/jac/dkv465. Epub 2016 Jan 28. J Antimicrob Chemother. 2016. PMID: 26825119 Free PMC article.
88 results